Overview of L Цет

Property	Description
Active ingredient	Levocetirizine dihydrochloride
Form	Oral tablet, Oral solution
Pharmacological class	Second-Generation Antihistamine; H1-receptor antagonist
Common use	Relief from allergic symptoms
Origin	Synthetic, Chiral Switch (R-enantiomer)

L Цет is the commercial designation for a pharmaceutical product containing the core active ingredient, Levocetirizine dihydrochloride. This medication is classified as a potent, synthetic Second-Generation Antihistamine belonging to the Piperazine Derivatives class. It is distinguished by its primary mechanism as an H1-receptor antagonist, an action clinically recognized for providing effective symptomatic relief from various allergic conditions.

Levocetirizine: Defining the Drug and Pharmacological Class

As a Second-Generation Antihistamine, Levocetirizine offers high selectivity for the H1 receptor, an attribute that generally differentiates it from older agents that often carry a higher risk of sedation. This distinction confirms the drug is designed to target allergy symptoms precisely while minimizing effects on the central nervous system. The medication is classified as an effective anti-allergic agent, with its general therapeutic purpose being to diminish the core manifestations of allergic conditions, such as skin itching or excessive discharge from the nose.

The Unique Composition and Form of L Цет

The active ingredient, Levocetirizine, is uniquely defined as the biologically active component, or R-enantiomer, of the older drug Cetirizine. This distinct purification is achieved through a chiral switch, a process ensuring the final product contains only the highly active form, or eutomer. This refined chemical identity contributes directly to its pharmacological potency. L Цет is a single-ingredient product available for oral administration in the dosage forms of a solid coated tablet and an oral solution.

What is the General Purpose of This Selective H1-Antagonist?

The general purpose of L Цет is to provide symptomatic relief by blocking the action of histamine, the key chemical messenger released during an allergic episode. Levocetirizine functions by binding to and deactivating the histamine H1 receptor on cells. By preventing the binding of histamine, the medication successfully halts the cascade of events that typically leads to common allergy manifestations, ultimately diminishing the body's inflammatory response.

Regulatory References

NIH: National Library of Medicine

What side effects are possible with L Цет?

Possible Side Effects and Safety Information

The safety profile of levocetirizine is defined by official regulatory documents, which classify adverse reactions based on their observed frequency in clinical trials and post-marketing surveillance. This information is organized into System-Organ Classes (SOCs) to clarify the spectrum of possible effects. The most frequently reported adverse reactions are generally related to the Nervous System and General Disorders, reflecting the drug's properties as a selective H1-antagonist.

Official Adverse Reactions by Frequency

Classification	Examples of Documented Effects
Common (1% to <10%)	Somnolence (drowsiness), Fatigue, Dry Mouth, Pharyngitis
Uncommon (0.1% to <1%)	Asthenia (weakness), Abdominal pain
Frequency Not Known	Hypersensitivity reactions (including Anaphylaxis), Convulsions, Hepatitis, Urinary retention

Serious Reactions and Safety Constraints

The most clinically significant but rare adverse reactions documented in the official labeling include severe Hypersensitivity Reactions (such as Angioedema or Anaphylaxis) and Convulsions. These are typically reported through post-marketing experience.

Contraindications are explicitly stated for patients with End-Stage Renal Disease (ESRD), defined as a creatinine clearance less than 10 mL/min, and for pediatric patients (6 months to 11 years) with impaired renal function. Use is also restricted for individuals with a known hypersensitivity to the drug or any other piperazine derivatives, such as Cetirizine. Regulatory warnings note that co-administration with alcohol or other CNS depressants may lead to additional impairment of Central Nervous System function and increased somnolence. Additionally, reports indicate a rare potential for severe Pruritus (itching) upon discontinuation following long-term daily use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Levocetirizine dihydrochloride (L Цет) overdose is defined by its Central Nervous System (CNS) manifestations and the necessary emergency response actions.

Domain	Official Regulatory Statement
Documented Manifestations	Overdose symptoms are age-dependent: Adults primarily experience Drowsiness and Somnolence. Children may exhibit initial Agitation and Restlessness before feeling sleepy.
Severe Presentation	Overdose at high multiples of the recommended dose may present with severe CNS effects including Confusion, Stupor, and Tachycardia (rapid heart rate).
Management Constraints	No specific antidote exists. Treatment is restricted to symptomatic and supportive care. Levocetirizine is not effectively removed by haemodialysis.

Emergency Action

Immediate medical help must be sought for any suspected overdose. Regulatory documents mandate contacting a Poison Control Center right away. Urgent emergency services must be called if the affected individual displays life-threatening symptoms, such as having a seizure, experiencing trouble breathing, or being unresponsive or unconscious.

This official information establishes the expected clinical presentation and defines the necessary immediate actions required by regulatory authorities.

Therapeutic Uses of L Цет

L Цет, containing levocetirizine dihydrochloride, is applied across domains where additional symptomatic support is needed. It is relevant for easing symptoms across therapeutic domains associated with acute or disruptive episodes. The medication is commonly used to help with symptoms in conditions such as Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria (CIU), offering supportive relief when symptoms interfere with routine activities.

Symptomatic Relief for Allergic Conditions

This medication is relevant for easing symptom clusters that may become intense or disruptive. It may assist with pronounced symptoms related to the nose and eyes, such as frequent sneezing, bothersome rhinorrhea, nasal pruritus, and discomforting tearing and ocular itching. In the dermal domain, it is applied in addressing persistent pruritus (skin itching) and may assist with supportive relief when wheals (raised welts) are present due to chronic hives. This supportive symptomatic relief assists with maintaining functional stability and supports the patient during difficult episodes by easing distress caused by uncomfortable reactions.

Symptom Focus: Allergic Itching L Цет is commonly used to help manage the pruritus associated with nasal allergies and also the skin itching seen in chronic hives.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define strict criteria for using Levocetirizine. The medicine is contraindicated in patients with a known hypersensitivity to the active ingredient, any excipients, or to any medicines categorized as piperazine derivatives (e.g., cetirizine).

Absolute exclusions also apply to patients with End-Stage Renal Disease, defined as a creatinine clearance (CLCr) less than 10 mL/min, and to all children aged 6 months to 11 years with any degree of renal impairment.

Population-Specific Rules

Use is permitted in adults, adolescents, and children starting from 6 months of age (using the oral solution formulation). However, the safety and efficacy are not established by regulators for infants under 6 months. Patients with mild to severe renal impairment (CLCr 10–80 mL/min) are eligible, but their use is restricted and requires specific management based on their kidney function. No dose adjustment is generally required for patients with solely hepatic impairment. Furthermore, the medicine is not recommended during breastfeeding due to excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of L Цет (levocetirizine dihydrochloride) based on pharmacodynamic effects and altered drug clearance, strictly identifying substances that require caution or avoidance.

Category	Interacting Substance / Outcome
Pharmacodynamic Interaction	Alcohol and CNS Depressants (general class) must be avoided to prevent additive impairment of central nervous system performance and additional reduction in alertness.
Exposure Modification	Ritonavir may increase levocetirizine plasma concentrations by reducing its total body clearance (a decrease of 29% in the racemate, cetirizine, is documented).
Minor PK Interaction	Theophylline (at a 400 mg dose) has been documented to cause a small decrease (16%) in the clearance of the racemate, cetirizine.
Food Interaction	Food does not reduce the extent of absorption of levocetirizine, though it officially decreases the rate of absorption.
Metabolic Pathway	Metabolism is minimal (less than 14% of the dose); therefore, pharmacokinetic interactions via CYP enzymes are unlikely to be clinically relevant.
Population Note	The risk of adverse effects from interactions may be more pronounced in the elderly and in patients with renal impairment, as the drug is substantially excreted by the kidneys.

No medicinal products are formally documented in regulatory labeling as strictly contraindicated for co-administration due to drug interaction risks. The defined interactions necessitate avoidance or caution related to the drug’s elimination pathway and its effects on the central nervous system.

Mechanism of Action

Selective Inverse Agonism on the Histamine mathbfH1 Receptor

The core mechanism involves Levocetirizine binding with high affinity to the Histamine mathbfH1 receptor found on cell surfaces throughout the body. The molecule acts as an inverse agonist, stabilizing the receptor in an inactive state to prevent both its own intrinsic activity and the activating effects of the endogenous mediator, histamine. This action interrupts histamine-driven signaling, which represents the primary molecular step in the acute inflammatory cascade.

Modulation of Vascular Permeability and Nerve Activation

This molecular action influences peripheral physiological processes, particularly those involving endothelial cells and sensory nerves. By deactivating H1 receptors on blood vessel linings, the mechanism restricts the histamine-induced increase in capillary permeability. Simultaneously, this action supports the regulation of peripheral nerve activity, dampening the histamine-driven stimulation of peripheral sensory nerves. The resulting physiological effect is a modulation of the vascular system and a dampening of the histamine-mediated physiological response at the tissue level.

Dosage and Administration Information

How L Цет (Levocetirizine) is Used: Official Dosing and Administration Principles

L Цет, containing levocetirizine dihydrochloride, is strictly approved for oral administration and is available as a 5 mg tablet and an oral solution. The medication is typically taken once daily, with the dose generally recommended for administration in the evening.

Standard Dosing and Administration Conditions

Age Group	Recommended Daily Dose	Administration Note
Adults and Adolescents (12 Years and older)	5 mg once daily	May be taken with or without food.
Children 6 to 11 Years	2.5 mg once daily	The maximum daily dose for this group is 2.5 mg.
Children 6 Months to 5 Years	1.25 mg once daily	Usually administered via the oral solution.

For administration, tablets must be swallowed whole. The 5 mg tablet is typically scored, allowing for it to be broken in half to achieve the 2.5 mg dose when necessary.

Population-Specific Use

Since levocetirizine is primarily eliminated by the kidneys, the dose must be reduced for patients with impaired renal function (kidney impairment). For adults with moderate impairment, the dose is generally reduced to 2.5 mg every other day, and it is contraindicated in patients with end-stage renal disease. For individuals with solely hepatic impairment, no dose adjustment is required.

Treatment duration is flexible; it may involve short-term, intermittent use for seasonal symptoms or long-term, continuous therapy for chronic conditions.

Recent Clinical Evidence

Research evidence / Overview of Studies for L Цет

This section provides an overview of the types of research and clinical trials that have been conducted to evaluate L Цет (levocetirizine), focusing strictly on what researchers studied and what the findings describe, without offering clinical recommendations or individual predictions.

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The evidence base for Seasonal Allergic Rhinitis (SAR), commonly known as hay fever, includes numerous short-term, double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over the typically brief periods of high pollen exposure.

In these trials, researchers examined patient-reported outcomes describing perceived discomfort, focusing on nasal and eye symptoms. Studies documented differences in the measured symptom scores between the treated group and the placebo group. Research documented the measurements recorded during the study period, which contextualize how patients reported their experience during acute allergic episodes. However, findings were mixed in some trials involving specific populations or geographical areas, which indicates that the results apply only to the conditions and populations studied.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria or CIU)

The research base exploring L Цет for Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of hives (wheals) and itching, includes medium-term, placebo-controlled RCTs. The primary focus of the research was on patient-reported outcomes describing perceived discomfort and physical changes in the skin. Reports documented the differences in the severity scores of symptoms and signs relative to the placebo after 4–6 weeks of administration in the studied populations. The evidence contributes to understanding symptom patterns in conditions associated with acute or disruptive skin episodes.

Long-Term Studies and Durability of Symptom Relief

Research has explored the patterns observed in symptoms and Quality of Life measures over prolonged exposure, primarily within Perennial Allergic Rhinitis long-term studies, which monitored outcomes over a period of up to six months. This extended evidence provides context on how symptoms and Quality of Life measures were observed during prolonged exposure. However, long-term effects are not fully established beyond the maximum follow-up duration of the core clinical trials.

Research Gaps and Areas of Uncertainty

Key limitations and areas of uncertainty are noted in the research landscape. Comparative evidence is lacking against all alternative medications in some key areas, meaning that subgroup findings are uncertain when comparing specific outcomes across all available therapies. Data for certain groups remain insufficient, and for instance, evidence for infants under six months of age is generally limited in the regulatory summaries.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about L Цет (FAQ)

Q: Is L Цет considered a 'non-drowsy' or a sedating antihistamine?

A: L Цет (levocetirizine) is categorized as a second-generation antihistamine, which typically has lower sedative effects compared to first-generation agents. However, official information notes that drowsiness (somnolence) and tiredness (fatigue) are still commonly reported side effects. A person's response to the medication should be monitored, as individual responses to sedation can vary.

Q: Is L Цет the same drug as cetirizine, or is it related?

A: L Цет and cetirizine are closely related but are not identical. Official pharmacological classification defines levocetirizine as the biologically active component (R-enantiomer) of the older drug, cetirizine. This chemical refinement means L Цет contains only the form of the molecule that produces the therapeutic effect.

Q: What kind of allergy symptoms is L Цет specifically designed to relieve?

A: Official labeling indicates that L Цет is used to relieve common symptoms of seasonal and perennial allergic rhinitis, such as runny nose, sneezing, and itchy, watery eyes. It is also indicated for the relief of itching associated with chronic hives (urticaria).

Q: Is L Цет safe for children of all ages to use?

A: The efficacy and general safety of L Цет have been established for use in children 6 months of age and older. However, official regulatory information specifies that safety is not established for infants younger than 6 months of age. Dosage and administration for pediatric patients are determined by a healthcare provider.

Q: What should I know about stopping L Цет after using it regularly for a long time?

A: Regulatory safety information warns of a potential reaction upon discontinuation following long-term daily use. This rare reaction is reported as severe generalized itching (pruritus).

Q: Is L Цет known to cause difficulty with urination or bladder problems?

A: Official labeling warns about the potential for the drug to cause urinary retention, which is the inability to completely empty the bladder. The labeling notes caution for individuals with factors that predispose them to urinary retention.

Q: Is L Цет safe for use in elderly patients (over 65 years old)?

A: Official information indicates that individuals 65 years of age and older may have an increased risk of adverse effects, and specialized guidance is provided for this population. This is based on the drug's properties and elimination pathway.

Q: Why do some people recommend taking L Цет in the evening instead of the morning?

A: The drug is generally recommended by regulatory bodies to be taken in the evening. This timing helps manage and minimize the impact of the common side effect of drowsiness (sleepiness) during the daytime hours.

Q: Does L Цет affect driving or operating machinery?

A: Official warnings state that because drowsiness may occur, individuals taking L Цет should use caution when driving a vehicle or operating machinery. This caution applies even without taking other sedating substances.

Q: Does L Цет work better than older-generation antihistamines?

A: The second-generation classification is related to the drug's high selectivity for the H1 receptor. This characteristic suggests a different safety profile, including reduced likelihood of central nervous system effects, compared to first-generation agents.

Q: Does L Цет help with sinus congestion or just runny nose?

A: The drug is indicated for relieving allergy symptoms that include runny nose. While the primary purpose is to manage allergic symptoms, nasal congestion or a stuffy nose is sometimes listed as a potential side effect, though it is not an intended use.

Q: How is L Цет's use described for seasonal vs. perennial allergies?

A: Official product information confirms that L Цет is used for the relief of symptoms associated with both seasonal allergic rhinitis (such as hay fever) and perennial allergic rhinitis (year-round allergies).

Q: Does L Цет have any known interaction with antidepressants or anxiety medication?

A: Official warnings specifically state that using alcohol or other Central Nervous System (CNS) depressants may increase side effects like drowsiness and reduced alertness. Many types of antidepressants and anxiety medications are classified as CNS depressants, which may necessitate caution.

Q: What is the maximum recommended length of time a person should continuously take L Цет?

A: The drug is approved for use in both short-term treatment for acute allergies and long-term treatment for chronic conditions like persistent hives. Official labeling does not specify an absolute maximum duration for continuous use; this is determined by the specific medical condition being managed.

Q: What are the possible signs of an allergic reaction to L Цет itself?

A: Symptoms of a severe allergic reaction that require immediate attention include rash, hives, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing. The official term for these severe reactions is Hypersensitivity.

Q: Can L Цет be taken with common pain relievers like paracetamol or ibuprofen?

A: Based on official interaction data, no significant drug-to-drug interactions were found between levocetirizine and common pain relievers such as paracetamol or ibuprofen. The defined interactions relate primarily to CNS depressants and certain prescription drugs.

Q: What is the general safety classification of L Цет for use during pregnancy?

A: Official labeling notes that the drug should be discussed with a health professional if an individual is pregnant or planning to become pregnant. This is standard guidance for many medications during pregnancy.

Q: What is the duration of action for a single dose of L Цет?

A: L Цет is generally administered once daily, which is reflective of its sustained effect. The drug has an elimination half-life (the time it takes for half of the drug to be cleared from the body) of approximately 8 to 9 hours.

Q: Can L Цет be purchased over-the-counter or is it only available by prescription?

A: The active ingredient, levocetirizine, is available in both over-the-counter (OTC) and prescription formulations, depending on the country, dosage strength, and specific product.

Q: Is it possible for L Цет to cause increased irritability or mood changes?

A: Official post-marketing surveillance reports list mood changes as rare side effects. These reported effects have included agitation, irritability, aggression, and depression.

Q: What does official information say about L Цет and risk of weight change?

A: Based on reports from post-marketing surveillance and clinical trials, an increase in weight is noted as an uncommon side effect of L Цет.

Q: Is there a risk of becoming dependent on L Цет for symptom relief?

A: Official regulatory warnings do not indicate a risk of physical dependency. L Цет is generally not considered to be a habit-forming medication.

How should L Цет be stored and disposed of?

Storage and Disposal of Levocetirizine 2HCl Tablets and Solution

Official Storage Conditions

Levocetirizine dihydrochloride must be stored at controlled room temperature, maintained between 20 C and 25 C (68 F to 77 F). The oral solution is explicitly prohibited from being frozen. To maintain product integrity, the tablets must remain in their original container, and the oral solution container must be kept tightly closed.

Protection and Disposal

All forms of the medication must be stored out of the sight and reach of children to prevent accidental ingestion. When the product is expired or unused, disposal must be carried out strictly according to local requirements for pharmaceutical waste. The official instruction prohibits disposing of the medicine by throwing it into household rubbish or flushing it down wastewater.

L Цет